Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Daptomycin: a cyclic lipopeptide antimicrobial agent.

LilyAnn Jeu1, Horatio B Fung

  • 1Pharmacy Service, VA Medical Center, Bronx, NY 10468, USA.

Clinical Therapeutics
|January 11, 2005
PubMed
Summary

Daptomycin shows efficacy for skin infections and resistant gram-positive pathogens. However, data on prolonged use or higher doses is limited, and it is not recommended for pneumonia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Clinical therapeutics·2012
Same author

Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.

Journal of pharmacy practice·2012
Same author

Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Clinical therapeutics·2012
Same author

Treatment of skin and soft tissue infections in the elderly: A review.

The American journal of geriatric pharmacotherapy·2011
Same author

Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.

Clinical therapeutics·2011
Same author

Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.

Clinical therapeutics·2010

Area of Science:

  • Pharmacology and Infectious Diseases
  • Antimicrobial Therapy Research

Background:

  • Daptomycin is a lipopeptide antibiotic.
  • Understanding its role in treating resistant infections is crucial.

Purpose of the Study:

  • To review daptomycin's pharmacology, pharmacokinetics, and efficacy.
  • To assess its safety profile and therapeutic applications.
  • To discuss its current and potential antimicrobial roles.

Main Methods:

  • Conducted a literature search of MEDLINE and International Pharmaceutical Abstracts (1966-August 2004).
  • Included review of conference abstracts and FDA documents.
  • Search terms: daptomycin, LY146032, lipopeptide antibiotics.

Main Results:

  • Daptomycin demonstrated comparable efficacy to vancomycin for skin infections.
  • It exhibits significant plasma protein binding and renal excretion.
  • Common adverse events include constipation, nausea, and muscle toxicity monitoring is advised.

Conclusions:

  • Daptomycin is effective for complicated skin infections and resistant gram-positive bacteria.
  • Limited data exists for treatment durations exceeding 14 days or doses above 4 mg/kg.
  • Daptomycin is not indicated for pneumonia.

Related Experiment Videos